EVOTEC ANNOUNCES FIRST FUNDED PROJECTS OF TRANSLATIONAL BRIDGE beLAB1407 IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 27 October 2021:

  • FIRST TWO PROJECTS FROM THE UNIVERSITIES OF BIRMINGHAM AND EDINBURGH SELECTED
  • beLAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first two projects to be developed within beLAB1407, a collaboration between Evotec and Bristol Myers Squibb to accelerate translational research from the UK’s academic life science ecosystem. Only six months after signing the beLAB1407 collaboration agreement in May 2021, the first projects to be developed within this academic BRIDGE collaboration have now been identified.

Read more

EVOTEC LAUNCHES “beLAB1407” TO ACCELERATE TRANSLATIONAL RESEARCH FROM THE UK’S ACADEMIC LIFE SCIENCE ECOSYSTEM IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 06 May 2021:

  • beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
  • THE COLLABORATION LEVERAGES EVOTEC’S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
  • BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.

Read more